Asthma patients who received vitamin D supplementation for 6 months had drastically fewer respiratory infections, linked to increased expression of the antimicrobial peptide cathelicidin LL-37 and shifts in immune markers.
Drastic reduction in respiratory infectionsAsthma patients receiving vitamin D for 6 months had significantly fewer respiratory infections, which correlated with increased cathelicidin LL-37 antimicrobial peptide levels in their sputum.
What the researchers found
Vitamin D supplementation (calcitriol) in asthma patients led to significantly increased serum levels of the anti-inflammatory cytokine IL-10 and the antiviral cytokine IFNγ, while pro-inflammatory cytokines IL-5, IL-9, and IL-13 decreased significantly. IgE and eosinophil levels also dropped, though allergen sensitivity remained unchanged.
Respiratory infections were drastically reduced in the vitamin D group, and this reduction was directly related to the number of patients who had high IL-10 and IFNγ levels and expressed the antimicrobial peptide cathelicidin LL-37 in their sputum. This links vitamin D's infection-fighting benefit to its ability to stimulate natural antimicrobial peptide production.
Why it matters
Respiratory infections are a leading trigger of asthma exacerbations. Finding that vitamin D can reduce infections by boosting the body's own antimicrobial peptide (cathelicidin LL-37) provides a mechanistic explanation for vitamin D's protective effects and suggests a simple, low-cost adjunct therapy that could improve outcomes for asthma patients.
How the study worked
Randomized, placebo-controlled trial with 86 asthma patients aged 18-50. Both groups received standard GINA-recommended asthma treatment. The treatment group additionally received calcitriol (1,25-(OH)₂D₃) for 6 months. At baseline and 6 months, researchers performed skin prick tests, pharyngeal bacterial cultures, sputum cathelicidin LL-37 measurements, and serum quantification of IgE, eosinophils, IL-5, IL-9, IL-10, IL-13, and IFNγ.
What this study cannot tell us
The sample size of 86 patients is moderate, and the study may not be powered to detect all relevant effects. Allergen sensitivity did not change, suggesting vitamin D's benefits may be limited to infection-related rather than allergic aspects of asthma. The study used calcitriol (active vitamin D) rather than standard vitamin D3 supplements, which may limit generalizability to typical supplementation regimens. Long-term effects beyond 6 months were not assessed.
How to read the evidence
This is a randomized, placebo-controlled trial — a strong study design. However, the moderate sample size of 86 patients and the lack of long-term follow-up limit the strength of the evidence. The results are biologically plausible and supported by mechanistic data.
When this study was published
Published in 2018, this study adds to a growing body of evidence connecting vitamin D to antimicrobial peptide-mediated immune defense. More recent studies have continued to explore this relationship.
The bigger picture
Cathelicidin LL-37 is one of the most studied antimicrobial peptides in humans, with broad activity against bacteria, viruses, and fungi. This study connects vitamin D's well-known immune benefits to a specific peptide mechanism — the upregulation of LL-37. This finding fits into a larger body of research exploring how endogenous antimicrobial peptides contribute to immune defense and how their production can be therapeutically modulated.
Questions still open
- Would standard vitamin D3 supplementation (rather than calcitriol) produce similar cathelicidin-mediated benefits?
- Could cathelicidin LL-37 levels serve as a biomarker for predicting which asthma patients will benefit most from vitamin D?
- Does this vitamin D-cathelicidin axis contribute to infection protection in other chronic respiratory diseases like COPD?
Common questions
How does vitamin D help fight respiratory infections?
Should asthma patients take vitamin D supplements?
Read the original research
Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNγ levels and cathelicidin expression.
Cytokine, 108, 239-246
Citation
Ramos-Martínez, E; López-Vancell, M R; Fernández de Córdova-Aguirre, J C; Rojas-Serrano, J; Chavarría, A; Velasco-Medina, A; Velázquez-Sámano, G. (2018). Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNγ levels and cathelicidin expression.. Cytokine, 108, 239-246. https://doi.org/10.1016/j.cyto.2018.01.001